Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Short-Term Debt issuances (2021 - 2024)

Harvard Bioscience (HBIO) has disclosed Short-Term Debt issuances for 4 consecutive years, with $3.2 million as the latest value for Q3 2024.

Quarterly Short-Term Debt issuances rose 225.0% to $3.2 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Jun 2025, down 56.95% year-over-year, with the annual reading at $8.8 million for FY2024, 95.56% up from the prior year.
Short-Term Debt issuances for Q3 2024 was $3.2 million at Harvard Bioscience, up from $3.0 million in the prior quarter.
The five-year high for Short-Term Debt issuances was $3.8 million in Q2 2022, with the low at $1.0 million in Q2 2023.
Average Short-Term Debt issuances over 4 years is $2.1 million, with a median of $2.1 million recorded in 2021.
The sharpest move saw Short-Term Debt issuances plummeted 73.68% in 2023, then skyrocketed 225.0% in 2024.
Over 4 years, Short-Term Debt issuances stood at $1.8 million in 2021, then surged by 42.86% to $2.5 million in 2022, then crashed by 60.0% to $1.0 million in 2023, then surged by 225.0% to $3.2 million in 2024.
According to Business Quant data, Short-Term Debt issuances over the past three periods came in at $3.2 million, $3.0 million, and $2.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.